Advancing precision medicines for patients with disorders of the central nervous system.
Grounded in data.
Our unique strategy at Leal integrates data from human genetics, physiology, pharmacology, and animal studies with a profound understanding of biological pathways to identify targets ripe for a precision therapeutic approach in the CNS.
Learn more about our approach here.
Driving the technology forward.
At Leal, we apply de-risked technologies to advance novel therapeutics. Our state-of-the-art nucleic acid and small molecule technology platform capabilities support our lead programs, allowing us to move safely and swiftly to patients.
Leal is also advancing novel, next-generation antisense oligonucleotide (ASO) technology platforms to maximize target engagement in the CNS.
Learn more about our platforms here.